At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 242 enrolled
Drug / intervention
Duloxetinedrug
Likely dose
Duloxetine 60 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Attributes of Response in Depressed Patients Switched to Treatment With Duloxetine (ARDENT Study)
In Brief
A Phase 4 clinical trial evaluating Duloxetine for Depressive Disorder, Major. Completed, enrolled 242 participants across 2 sites.
Detailed Summary
The purpose of this study is to help answer the following research question: Whether switching to duloxetine improves depressed mood when current treatment did not work well for patients with depression.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDepressive Disorder, Major
CountriesSouth Korea
Collaborators--
Timeline
Phase 4CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartJun 2008
First PostedJun 2008
Primary CompletionJul 2009
TodayJul 2026
First PostedJun 13, 2008
Enrollment StartJun 1, 2008
Primary CompletionJul 1, 2009
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 18.1 years ago
Interventions
Duloxetinedrug
Study Period II (Acute Therapy): 60 mg capsules, QD, for 4 weeks. Study Period III (Optimization): Responder group - 60 mg capsules, QD, for 4 weeks more. Non-responder group - 120 mg capsules, QD, for 4 weeks more.